Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 or COVID-19 is representing the major global burden that implicated more than 4.7 million infected cases and 310 thousand deaths worldwide in less than 6 months. The prevalence of this pandemic disease is expected to rise every day. The challenge is to control its rapid spread meanwhile looking for a specific treatment to improve patient outcomes. Hesperidin is a classical herbal medicine used worldwide for a long time with an excellent safety profile. Hesperidin is a well-known herbal medication used as an antioxidant and anti-inflammatory agent. Available shreds of evidence support the promising use of hesperidin in prophylaxis and treatment of COVID 19. Herein, we discuss the possible prophylactic and treatment mechanisms of hesperidin based on previous and recent findings. Hesperidin can block coronavirus from entering host cells through ACE2 receptors which can prevent the infection. Anti-viral activity of hesperidin might constitute a treatment option for COVID-19 through improving host cellular immunity against infection and its good anti-inflammatory activity may help in controlling cytokine storm. Hesperidin mixture with diosmin co-administrated with heparin protect against venous thromboembolism which may prevent disease progression. Based on that, hesperidin might be used as a meaningful prophylactic agent and a promising adjuvant treatment option against SARS-CoV-2 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.003 · Cited by 1,288 · cited 2×
“Cytokine storm involves the release of various immune-active molecules such as Interferons (e.g. IFNγ), interleukins (e.g. IL-1β, IL-2, IL-6), chemokines, and tumor necrosis factor-alpha (TNF-α) [16].”
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126
Cited by
Osorio, L. L. D. R., Flórez-López, E., & Grande-Tovar, C. D. (2021) · Molecules · doi:10.3390/molecules26020515 · Cited by 367
Traditional Chinese medicine in COVID-19
Lyu, M., Fan, G., Xiao, G., Wang, T., Xu, D., Gao, J., Ge, S., Li, Q., Ma, Y., Zhang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.008 · Cited by 224
Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits
Bellavite, P., & Donzelli, A. (2020) · Antioxidants · doi:10.3390/antiox9080742 · Cited by 207
Parisi, G. F., Carota, G., Castruccio Castracani, C., Spampinato, M., Manti, S., Papale, M., Di Rosa, M., Barbagallo, I., & Leonardi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052465 · Cited by 43
Metadata
- Authors
- Haggag, Y. A., El-Ashmawy, N. E., & Okasha, K. M.
- Venue
- Medical Hypotheses
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 144
- Pages
- 109957
- ISSN
- 0306-9877 (ISSN-L)
- OpenAlex
- W3033805824
- Cited by
- 125
- References
- 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? https://app.cochat.ai/papers/10.1016/j.mehy.2020.109957
- The paper
- Haggag, Y. A., El-Ashmawy, N. E., & Okasha, K. M. (2020). Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Medical Hypotheses. https://doi.org/10.1016/j.mehy.2020.109957
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.